Steven Cohen’s Maravai LifeSciences MRVI Stock Holding History

Steven Cohen’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.5M	Sell	2,005,579 -1,199,917	-37%	-$5.18M	0.01%	1145
2026 Q1	$9.07M	Buy	3,205,496 +357,697	+13%	+$1.21M	0.01%	1314
2025 Q4	$9.26M	Buy	2,847,799 +2,815,057	+8,598%	+$9.48M	0.01%	1405
2025 Q3	$94K	Buy	+32,742	New	+$83.6K	﹤0.01%	2211
2024 Q4	–	Sell	-1,026,749	Closed	-$8.53M	–	2314
2024 Q3	$8.53M	Sell	1,026,749 -2,492,812	-71%	-$21.5M	0.02%	698
2024 Q2	$25.2M	Buy	3,519,561 +2,109,199	+150%	+$18.2M	0.07%	344
2024 Q1	$12.2M	Buy	1,410,362 +459,162	+48%	+$3.11M	0.03%	643
2023 Q4	$6.23M	Buy	+951,200	New	+$6.15M	0.02%	844
2023 Q3	–	Sell	-460,111	Closed	-$5.72M	–	2731
2023 Q2	$5.72M	Buy	+460,111	New	+$6.21M	0.02%	769
2022 Q4	–	Sell	-151,000	Closed	-$3.85M	–	1694
2022 Q3	$3.85M	Buy	+151,000	New	+$3.79M	0.02%	794
2022 Q1	–	Sell	-390,900	Closed	-$13.1M	–	1307
2021 Q4	$16.4M	Buy	390,900 +261,412	+202%	+$10.6M	0.07%	379
2021 Q3	$6.36M	Buy	+129,488	New	+$6.32M	0.03%	608
2021 Q1	–	Sell	-493,883	Closed	-$13.9M	–	1099
2020 Q4	$13.9M	Buy	+493,883	New	+$13.8M	0.07%	366

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Steven Cohen's MRVI Position: Q2 2026 in Review

Steven Cohen reduced its Maravai LifeSciences (MRVI) stake by 37% in Q2 2026, selling an estimated $5.18M and leaving 2,005,579 shares worth $12.5M. The position accounts for 0.01% of the portfolio, ranked #1145.

Steven Cohen first reported a position in MRVI in Q4 2020 and has held it in 13 quarters since. The position peaked at $25.2M in Q2 2024. 177 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Steven Cohen held 2,005,579 shares of Maravai LifeSciences worth $12.5M as of Q2 2026.
Steven Cohen sold 1,199,917 Maravai LifeSciences shares in Q2 2026, an estimated $5.18M.
Maravai LifeSciences made up 0.01% of Steven Cohen's portfolio in Q2 2026, its #1145 holding.
Steven Cohen first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 13 quarters since.
Steven Cohen's Maravai LifeSciences position peaked at $25.2M in Q2 2024.
177 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.